Compare UP & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UP | CADL |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | 1250 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.6M | 357.4M |
| IPO Year | N/A | 2021 |
| Metric | UP | CADL |
|---|---|---|
| Price | $0.43 | $5.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $4.34 |
| 52 Week High | $3.50 | $7.24 |
| Indicator | UP | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 52.99 |
| Support Level | $0.41 | $4.57 |
| Resistance Level | $0.59 | $5.25 |
| Average True Range (ATR) | 0.06 | 0.23 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 37.43 | 84.97 |
Wheels Up Experience Inc is a provider of on-demand private aviation. The company offers a private aviation solution with a large and diverse aircraft fleet, delivered through a mix of charter solutions and its membership program that utilizes its controlled aircraft fleet and a network of safety-vetted charter operators. Through its partnership firm, it provides members and customers with an offering across private and premium commercial travel. It generates the majority of its revenue from member and customer flights through its membership program and charter solutions, as well as from membership fees and other activities and services, including group charter flights, cargo flights, and special missions. Geographically, the company generates maximum revenue from the United States.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.